BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//NextToU//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:e168711e-5bcd-4630-824e-464c4d1174bf@nexttoyou
DTSTAMP:20261105T154721Z
DTSTART:20261109T200000Z
DTEND:20261109T210000Z
SUMMARY:Cancer Therapeutics Training (CT2) Talk | Matthew Shtrahman\, MD\,
  PhD
LOCATION:Comer Commons\, Moores Cancer Center
DESCRIPTION:Toxicity to Opportunity: Harnessing AAV Biology to Treat Pedia
 tric Brain Cancers\n\nDr. Shtrahman received his undergraduate degree in 
 Biochemistry from the University of Michigan. He returned to his hometown
  to obtain his MD and PhD degrees at the University of Pittsburgh\, where
  he did his thesis work with Dr. Xiao-lun Wu in the Department of Physics
 . He completed his residency training and clinical neurophysiology fellow
 ship in the Department of Neurology at UCLA. Dr. Shtrahman went on to do 
 his postdoctoral training with Dr. Tom Otis at UCLA and subsequently Dr. 
 Fred Gage at the Salk Institute before joining the faculty of the Departm
 ent of Neurosciences at UCSD in 2016. His lab studies how adult-born and 
 mature neurons in the brain encode memories and become altered in disease
 s of the nervous system. Building on work showing that the widely used re
 combinant adeno-associated virus (AAV) kills dividing neural progenitor c
 ells and ablates neurogenesis in the murine dentate gyrus\, Dr. Shtrahman
  and his team are investigating the molecular mechanisms as well as the t
 ranslational and therapeutic implications for this phenomenon. They hope 
 to capitalize on these findings to develop new AAV-based treatments for b
 rain tumors and other lethal cancers that are amenable to local treatment
 .\n\nhttp://next-to-u.app/events/e168711e-5bcd-4630-824e-464c4d1174bf
URL:http://next-to-u.app/events/e168711e-5bcd-4630-824e-464c4d1174bf
END:VEVENT
END:VCALENDAR